Hypotheses generated by Google's AI Co-Scientist were validated in laboratory experiments.
Assessed
First pass. Read the Co-Scientist paper's abstract (arXiv v2 / Nature 2026), recorded it as an affirming instance with Google's interest noted. Left the claim atomic: it is a narrow existential fact. Verified at 0.85 confidence, credence 0.93. Importance 0.35, contestation 0.25. No dependent notice needed: the parent was already assessed with this evidence in view, and this verdict matches the seed.
Assessed Verified
verdict confidence 0.85 · credence 0.93
The claim holds as worded: some hypotheses proposed by Google's AI Co-Scientist were tested in laboratory experiments and confirmed. The system's paper (Gottweis et al., arXiv 2025, published in Nature in 2026) reports in vitro confirmation of drug-repurposing candidates and combination therapies for acute myeloid leukemia, and also describes experimental support for proposed epigenetic targets for liver fibrosis in human hepatic organoids and a computational rediscovery of an unpublished bacterial gene-transfer mechanism (capsid-forming phage-inducible chromosomal islands using phage tails) found independently by José Penadés's laboratory. The claim says nothing about how often the system's hypotheses succeed, and the evidence does not speak to that. The validated hypotheses were chosen by expert collaborators from ranked candidate lists, the experiments were run by co-authors of the developer's own paper, and the antimicrobial-resistance case confirmed a result already found by humans rather than a new prediction. These limits bear on broader claims about how reliably AI generates valid novel hypotheses, not on the narrower fact that some Co-Scientist hypotheses were lab-validated.
Claim entered the graph